Ravena R. P. da Silva
Research Subjects
Ravena R. P. da Silva has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ahmad Abubakar1 shared publication
- Claudia Veronica Da Silva Crispim
Aging and Cardiovascular Discovery Center, Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA
1 shared publication - Daniel Gedder Silva
Center for the Research and Advancement in Fragments and molecular Targets (CRAFT), School of Pharmaceutical Sciences at Ribeirao Preto
1 shared publication - Maurício F. de Lima1 shared publication
- Tiago H. C. da Silva1 shared publication
Latest Publications
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Miniaturized Reaction Platforms in Drug Discovery: from Synthesis to Direct-to-Biology Screening
The increasing demand for faster, more efficient drug discovery has exposed fundamental limitations in conventional design-make-test-analyze workflows, particularly regarding scalability, resource consumption, and reliance on purification-intensive processes. Miniaturized synthetic platforms have emerged not merely as a technical refinement, but as a paradigm shift integrating chemical synthesis and biological evaluation. This review examines miniaturization as a framework enabling the direct coupling of compound generation and biological screening, with emphasis on direct-to-biology strategies. A systematic assessment of the literature reveals convergence toward simplified, high-efficiency reaction formats compatible with automation and minimal purification. These platforms rely on a limited set of robust transformations, with amide coupling accounting for 42% of reported reactions, followed by multicomponent reactions (15%), click chemistry (14%), carbonyl-amine transformations (12%), and nucleophilic aromatic substitution (9%), while metal-catalyzed reactions remain underrepresented (3%). This distribution reflects a preference for high-yielding, operationally simple, and biocompatible reactions that tolerate crude conditions and enable direct screening. The integration of analytical and computational tools supports real‑time decision-making and accelerates structure-activity relationship exploration. Notably, efforts remain concentrated in oncology and infectious diseases, with a clear absence of applications targeting parasitic neglected tropical diseases. Collectively, these approaches redefine early-stage drug discovery by compressing timelines and reducing costs.
- 1 January 2026
- Published by Sociedade Brasileira de Quimica (SBQ) in Journal of the Brazilian Chemical Society
Miniaturized Reaction Platforms in Drug Discovery: from Synthesis to Direct-to-Biology Screening
The increasing demand for faster, more efficient drug discovery has exposed fundamental limitations in conventional design-make-test-analyze workflows, particularly regarding scalability, resource consumption, and reliance on purification-intensive processes. Miniaturized synthetic platforms have emerged not merely as a technical refinement, but as a paradigm shift integrating chemical synthesis and biological evaluation. This review examines miniaturization as a framework enabling the direct coupling of compound generation and biological screening, with emphasis on direct-to-biology strategies. A systematic assessment of the literature reveals convergence toward simplified, high-efficiency reaction formats compatible with automation and minimal purification. These platforms rely on a limited set of robust transformations, with amide coupling accounting for 42% of reported reactions, followed by multicomponent reactions (15%), click chemistry (14%), carbonyl-amine transformations (12%), and nucleophilic aromatic substitution (9%), while metal-catalyzed reactions remain underrepresented (3%). This distribution reflects a preference for high-yielding, operationally simple, and biocompatible reactions that tolerate crude conditions and enable direct screening. The integration of analytical and computational tools supports real‑time decision-making and accelerates structure-activity relationship exploration. Notably, efforts remain concentrated in oncology and infectious diseases, with a clear absence of applications targeting parasitic neglected tropical diseases. Collectively, these approaches redefine early-stage drug discovery by compressing timelines and reducing costs.